We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Conjugated Linoleic Acid
A group of fatty-acid isomers heavily marketed as a fat-loss aid. The honest picture: meta-analyses of human trials show only a small, inconsistent reduction in fat mass that the authors themselves call clinically uncertain — and the active t10c12 isomer has actually WORSENED insulin sensitivity and lowered HDL in obese men.
What the evidence says
Most CLA studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2002–2012 with a typical study size of 60 participants.
Based on 4 studies · 2 meta-analyses · 1 RCT · 60 total participants
Confidence
HighBy outcome
CLA has an evidence score of 3/10 — emerging evidence based on 4 indexed studies, including 2 meta-analyses. A group of fatty-acid isomers heavily marketed as a fat-loss aid. The honest picture: meta-analyses of human trials show only a small, inconsistent reduction in fat mass that the authors themselves call clinically uncertain — and the active t10c12 isomer has actually WORSENED insulin sensitivity and lowered HDL in obese men. Representative study: PMID 21990002.
The commonly studied dose of CLA is 3.2-3.4g daily of CLA isomer mix (the dose used in most trials; benefit remains small/uncertain). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Explore: Best supplements for Vitality & LongevityBest supplements for Athletic Performance
Last reviewed June 2026 · evidence from 4 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Conjugated linoleic acid (CLA) is a family of positional and geometric isomers of linoleic acid, sold as a body-composition supplement on the strength of dramatic fat-loss effects seen in mice. In humans the story is far weaker. The two most-cited human meta-analyses (Whigham 2007; Onakpoya 2012) find at most a small fat-mass reduction (~1.3 kg over many months) that the authors describe as of 'uncertain' clinical relevance, with serious methodological flaws in several included trials and no convincing effect on body weight. More concerning, the purified trans-10,cis-12 isomer — the one thought to drive fat loss — increased insulin resistance by ~19% and lowered HDL cholesterol in a controlled trial of abdominally obese men (Risérus 2002). So CLA is a case where the marketing outruns the evidence, and where the 'active' isomer carries a real metabolic downside. We score it low and emerging.
In rodents the t10c12 isomer reduces fat storage and increases fat oxidation; these effects are far smaller and less consistent in humans.
Proposed modulation of adipocyte differentiation and lipid-handling enzymes — mechanistic, and the same pathway implicated in the adverse insulin/HDL signals.
How CLA works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
3.2-3.4g daily of CLA isomer mix (the dose used in most trials; benefit remains small/uncertain)
Take with food
| Form | Type |
|---|---|
| 💊CLA isomer mixture | Recommended |
| 💊Tonalin (safflower-derived CLA) | Alternative |
Avoid isolated t10c12 isomer due to adverse metabolic signals.
Minimum: 12 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Split across meals; take with food.
Dose-response data unavailable. The current published research for CLA does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Meta-analyses find a small fat-mass effect that authors call of uncertain clinical relevance.
Purified t10c12 CLA increased insulin resistance ~19% in obese men.
Constipation, diarrhea, and soft stools reported in trials.
Avoid — t10c12 CLA worsened insulin sensitivity in obese men with metabolic syndrome.
Not established as safe — avoid.
CLA (especially the t10c12 isomer) has worsened insulin sensitivity and raised glycemia in trials — may oppose glucose control.
CLA has lowered HDL cholesterol in trials — an unfavorable lipid shift.
Tip: Take with food; discontinue if persistent
Tip: Monitor lipids; avoid in those with low HDL
Tip: Avoid isolated t10c12; caution in metabolic syndrome
Both are marketed as fat-loss aids via thermogenic/lipid-metabolism mechanisms; combined evidence remains modest.
Layered (but weakly-evidenced) body-composition support.
Caffeine has more robust (if modest) thermogenic/fat-oxidation data than CLA and is often co-formulated in weight products.
Caffeine carries the stronger evidence of the pair.
The best time to take CLA is with meals. Take it with food. Fat-soluble; taken with meals to reduce GI upset.
CLA should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are GI upset (constipation, diarrhea, soft stools), reduced HDL cholesterol, increased insulin resistance (t10c12 isomer). Use caution if any of these apply to you: Metabolic syndrome / insulin resistance / type 2 diabetes (t10c12 worsened insulin sensitivity); Pregnancy/breastfeeding (not established as safe).
Activates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Tap node to isolate • Pinch to zoom • Tap edge for research